Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma

International Journal of Cancer. Journal International Du Cancer
Ryuta SaitoJun Yoshida

Abstract

Interferon-beta (IFN-beta) has been used as an antitumor drug against human glioma, melanoma and medulloblastoma since the 1980s. Recently, we developed a new gene therapy using the IFN-beta gene against malignant gliomas and then began clinical trials in 2000. Since stimulation of immune system was one mechanism of antitumor effect induced by IFN-beta gene therapy, we hypothesized that combination of IFN-beta gene therapy with immunotherapy might increase its effectiveness. In the present study, we tested whether combination therapy with IFN-beta gene therapy and immunotherapy using tumor cell lysate-pulsed dendritic cells (DCs) would increase the efficacy of IFN-beta gene therapy. In an experimental mouse intracranial glioma (GL261), which cannot be cured by either IFN-beta gene therapy or DC immunotherapy alone, IFN-beta gene therapy following DC immunotherapy resulted in a significant prolongation in survival of the mice. Moreover, when this combination was performed twice, 50% of treated mice survived longer than 100 days. Considering these results, this combination therapy may be one promising candidate for glioma therapy in the near future.

References

Jan 1, 1991·Annual Review of Immunology·J J OppenheimK Matsushima
Mar 22, 1996·Science·D R LeachJ P Allison
Mar 26, 1999·European Journal of Immunology·D PillingM Salmon
Sep 12, 2000·Journal of Neuro-oncology·A NatsumeJ Yoshida
Mar 21, 2001·Human Molecular Genetics·P Y Lam, X O Breakefield
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·S BrandauA Böhle
Mar 9, 2002·Journal of Neurosurgery·Vladimir V DidenkoDavid S Baskin
Mar 21, 2002·Cancer Immunology, Immunotherapy : CII·Marcella RealePio Conti
Jun 5, 2003·Current Opinion in Oncology·Carlo MarrasFrancesco DiMeco
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ya-Wen HsiaoRea-Min Chu

❮ Previous
Next ❯

Citations

Mar 20, 2012·Leukemia·S NaikS J Russell
May 2, 2014·Journal of Translational Medicine·Taemin OhAndrew T Parsa
Dec 2, 2010·Cancer Immunology, Immunotherapy : CII·Wim Maes, Stefaan W Van Gool
Nov 26, 2015·Immunotherapy·Anda-Alexandra CalinescuMaria Graciela Castro
Oct 4, 2005·Neurological Research·Christian W Sikorski, Maciej S Lesniak
Oct 22, 2013·Neurologia Medico-chirurgica·Yohei MineharuSusumu Miyamoto
Jul 15, 2015·BioMed Research International·Liu YangJing Liu
Sep 12, 2009·Brain Pathology·Stefaan Van GoolSteven De Vleeschouwer
Jul 20, 2005·Expert Review of Neurotherapeutics·Yasuharu AkasakiJohn S Yu
Sep 3, 2005·Cancer Gene Therapy·S E LawlerE A Chiocca
Apr 21, 2006·Expert Review of Neurotherapeutics·Maciej S Lesniak
Dec 25, 2012·Journal of Neuro-oncology·Marian Christoph NeidertStefan Stevanović
Nov 25, 2020·Journal of Experimental & Clinical Cancer Research : CR·Yuanliang YanZhijie Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.